AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02669628 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical technique
Description: Laparoscopic surgery
Study NCT02669628 — intervention group
Intervention type: PROCEDURE
Intervention: Alcohol sclerotherapy
Description: US-guided sclerotherapy
Study NCT02816554 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JEVAX
Description: JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
Study NCT02816554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-1
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
Study NCT02816554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-0.8
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
Study NCT02816554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JECEVAX-0.5
Description: JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carbon-monoxide rebreathing
Description: Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbon-monoxide rebreathing
Description: Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: venous blood sampling
Description: venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: venous blood sampling
Description: venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical activity monitoring
Description: recording of physical activity by actimetry
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity monitoring
Description: recording of physical activity by actimetry
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: apnea-hypopnea index and nocturnal oxygenation
Description: recorded by ambulatory sleep recording device
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnea-hypopnea index and nocturnal oxygenation
Description: recorded by ambulatory sleep recording device
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour blood pressure
Description: recorded by ambulatory device
Study NCT04106401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure
Description: recorded by ambulatory device
Study NCT01715415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study NCT01715415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)
Study NCT01715415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-450/r/ABT-267
Description: Tablet
Study NCT01715415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-333
Description: Tablet
Study NCT01715415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Ophthalmic solution to be applied as directed.
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic solution to be applied as directed.
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study NCT01959230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study NCT04112615 — intervention group
Intervention type: DEVICE
Intervention: Blood measurement
Description: Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
Study NCT02586688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
Description: Compare active NeuroStar® coil with sham NeuroStar® coil.
Study NCT02586688 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
Description: Compare active NeuroStar® coil with sham NeuroStar® coil.
Study NCT02586688 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Open Label Active NeuroStar® TMS
Description: Open label NeuroStar® coil.
Study NCT00478634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Cetuximab, Irinotecan
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 1 (10 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 10 μg/kg, Intramuscular injection, given once.
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 1, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 2 (35 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 35 μg/kg, Intramuscular injection, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 2, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 3 (100 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 100 μg/kg, Intramuscular injection, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 3, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM002 Dosage 4 (250 μg/kg)
Description: TNM002 (human monoclonal antibody against tetanus toxin), 250 μg/kg, Intramuscular injection, given once
Study NCT04629131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match TNM002 Dosage 4, given once
Study NCT02239601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
Study NCT02902666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet
Study NCT02902666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet
Study NCT03181178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macro-micronutrient complementary food supplement
Description: This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
Study NCT03181178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A micronutrient powder
Description: This intervention provided a 1 g micronutrient powder with nutrition education
Study NCT03181178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: This intervention provided nutrition education sessions
Study NCT00276965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
Study NCT00276965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Description: Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
Study NCT05049304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional olive oil
Description: Eleven adolescents will consume OA-enriched functional olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
Study NCT05049304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: Eleven adolescents will consume olive oil. After eating the olive oil, aliquots of cubital blood will be drawn at 2 and 5 hours of the postprandial period. During that time, free access to water intake will be allowed.
Study NCT02276911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT00958958 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: multifaceted strategy
Description: There are multifaceted Interventions Including~1. Distribution of educational materials: distribution of published or printed recommendations for clinical care.~2. Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~3. Reminders~4. Practical training
Study NCT00793871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate (SU011248)
Description: Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
Study NCT01801943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy Group
Description: 30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
Study NCT01801943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention (WI) Group
Description: 60 min Walking Intervention + 30 min low interface reading 3x week
Study NCT01801943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination Group
Description: 30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
Study NCT01801943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Group
Description: 60 Min Healthy Living class + 30 min low interface reading 3x week
Study NCT00573690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00573690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT01745263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Home Exercise
Study NCT01745263 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Flexibility Home Exercise
Study NCT00573690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00573690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT00573690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT02276911 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT01256346 — intervention group
Intervention type: DEVICE
Intervention: Apparatuses
Description: Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
Study NCT03798015 — intervention group
Intervention type: OTHER
Intervention: mitral valve surgery
Description: assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
Study NCT03583580 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
Study NCT02219880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kava (240mg of kavalactones per day)
Description: Kava 60 milligrams per tablet = 240mg of kavalactones per day
Study NCT02219880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
Study NCT00485719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
Study NCT02263560 — intervention group
Intervention type: BEHAVIORAL
Intervention: Kinematic measurements
Study NCT01322243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary manipulation
Description: Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
Study NCT00256074 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral feeding formula
Study NCT01608750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazol
Description: 40mg/day, oral, 28 days
Study NCT01608750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: 5 mg/day, oral, 28 days
Study NCT04047667 — intervention group
Intervention type: PROCEDURE
Intervention: cone beam CT guided transbronchial cryobiopsy
Description: CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
Study NCT03191383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 1
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study NCT03191383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 2
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study NCT03191383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV vaccine (GSK3003891A) formulation 3
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study NCT03191383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Formulation buffer S9b)
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Study NCT03666130 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic septoplasty
Description: endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
Study NCT00980863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention to increase physical activity
Study NCT00980863 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: lifestyle intervention to increase physical activity
Study NCT01205776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
Study NCT01808313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
Study NCT03072901 — intervention group
Intervention type: DEVICE
Intervention: EndoBarrier Gastrointestinal Liner
Description: The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
Study NCT03947645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipsilesional stimulation
Description: Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
Study NCT03947645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralesional stimulation
Description: Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 50 mg nano-suspension (reference)
Description: Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation - fed
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole and AZD4635 50 mg solid oral formulation
Description: Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation variant 1 - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635 solid oral formulation variant 2 - fasted
Description: Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
Study NCT03710434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD4635 IV microtracer - fasted
Description: Subjects will receive a single dose of \[14C\] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
Study NCT00816517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: injection of botulinum toxin type A.
Description: 35 to 100 units injected around a skin lesion (plaque) one time.
Study NCT03943368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceevra Reveal
Description: 3D Digital models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source MR image.
Study NCT01388387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tacrolimus pharmacokinetics
Description: tacrolimus pharmacokinetics over 12 hours
Study NCT01631032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi-tonifying Chinese herbal products
Description: Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
Study NCT04790409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab and anlotinib
Description: This study was a one-arm, open-label, phase II study of PD-1 monoclonal antibody combined with ilotinib in the treatment of advanced EGFR rare-mutant non-small cell lung cancer (NSCLC). 21 patients enrolled in the study who underwent platinum-containing systemic chemotherapy and EGFR-TKI failure were enrolled in the study.
Study NCT01752322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster
Study NCT01752322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plaster